Stoke Therapeutics, Inc. (STOK) — closed signal from January 22, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 22, 2026.
Predicted vs. what happened
What happened
Reached its target in 32 days.
The thesis — published January 22, 2026
Stoke looks like a short-term rebounding biotech: selling pushed the stock down, but clear trial timelines and a mid-2027 data readout give a visible path for the stock to recover if sentiment improves. Buy in stages inside the zone and aim for a return toward the prior trading area. Main danger is biotech volatility or bad trial or regulatory news.
Primary drivers
- Clear Phase 3 timeline keeps upcoming news visible
- Recent heavy selling could lead to a quick rebound
- Events and conferences can bring specialist buyers back
- Stock swings more, so it can rise faster if risk appetite returns
How it played out
STOK: target reached in 32 days
Lyra published STOK at $30.16 on 2026-01-22 with a short-term thesis for 20% growth toward $36.19. The thesis pointed to a clear Phase 3 timeline, recent heavy selling, events and conferences, and the stock's higher swing profile as reasons a rebound could happen if sentiment improved.
Inside the window, STOK rose above the target. It peaked at $40.22 on 2026-03-10, with a 33.4% gain, and reached the target in 32 days. It ended the window at $35.90 on 2026-04-22. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.